Overview

Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

Status:
Recruiting

Trial end date:
2027-02-01

Target enrollment:

Participant gender:

Summary

Patients with CD30 positive DLBCL, primary refractory or in first relapse after R-CHOP or R-CHOP-like therapy will receive brentuximab vedotin in combination with R-DHAP, followed in responsive patients by high dose chemotherapy and ASCT.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Stichting Hemato-Oncologie voor Volwassenen Nederland

Treatments:

Antibodies, Monoclonal
Brentuximab Vedotin